Discover new targets. Run more efficient trials. Get your therapies to market sooner.

Foundation Medicine is your partner to help accelerate biomarker-driven drug development —from target discovery to commercial launch. With more data, more partnerships, and a dynamically connected network of physicians, medical centers, patients, and academic researchers, we are helping biopharmaceutical companies drive precision medicine forward, in the pursuit of better outcomes for patients.

Overview

Partnering with Foundation Medicine

  • Research

    Our partners can leverage our genomic knowledgebase in their clinical scientific investigations or use our assays to perform biomarker discovery in prospective and retrospective clinical specimens.

  • Development

    We facilitate molecularly guided clinical trial design by connecting patients with trials, targeting their unique genomic profiles. We utilize our comprehensive genomic platform as a Clinical Trial Assay (CTA) for prospective patient selection.

  • Commercialization

    We offer comprehensive Companion Diagnostic development, full regulatory support services (including submissions), as well as integrated post-approval services.

Biomarker Discovery

Foundation Medicine is a world leader in cancer genomics research and its translation into actionable clinical tests. We collaborate with our partners in biomarker-driven drug development — from target discovery to commercial launch.

Researchers reviewing findings on a tablet.

Comprehensive Genomic Profiling

Foundation Medicine offers comprehensive genomic profiling of clinical trial samples in our CLIA-permitted and CAP-accredited laboratory utilizing our panel of diagnostic tests: FoundationOne®, FoundationOne® Heme, and FoundationACT®.

We support genomic screening for patient access to clinical trials, retrospective analyses, as well as sponsor-initiated research studies. We offer expert follow-up analysis of the genomic data we generate, including de novo biomarker signature discovery.

Learn more about our assays

Innovation Begins with Robust Data

FoundationCore™ is one of the largest genomic datasets in the world. It is notably enriched for rare cancers relative to population prevalence, making it an invaluable source for genomic targeting of populations with high unmet medical need.

Through our partnerships with Flatiron Health and IMS Health, Foundation Medicine provides Molecular Information Solutions, analyzing and integrating clinical treatment and outcomes data with matched comprehensive genomic profiling.

Learn more about FoundationInsights

“The collaboration with Foundation Medicine has broadened the scope of our clinical programs and has pointed us in new, unique directions and we look forward to continuing this successful collaboration.”

Markus Warmuth, MD

President and CEO of H3 Biomedicine

Optimizing Clinical Trials

Biomarker-driven clinical trials are becoming increasingly relevant in oncology. Optimizing these clinical trials from a design, planning, and enrollment perspective has proved challenging due to the economic and logistical challenges of recruiting rare patient cohorts. Foundation Medicine is uniquely positioned to address these issues with our FoundationSmartTrials ™ services.

Older man fills out a form at his doctor's office.

Comprehensive Support Services for Clinical Trials

Foundation Medicine is charting a new model for drug development in an era of targeted oncology therapies. We sit at a nexus of medicine and pharmaceutical research, combining our multifaceted expertise, more than 120,000 sequenced patient samples, and more than 30 pharmaceutical partners.

Experience from this unique position allows us to help clinical research sponsors to better design and run trials.

We offer clinical program design and indication expansion. We also build applications to help patients find matching trials and biopharma companies find matching patients.


Your Guide Through Approval and Commercialization

The Preferred Partner for Companion Diagnostics

Foundation Medicine offers a first-in-class next-generation sequencing (NGS) cancer assay with the potential to incorporate multiple companion diagnostic (CDx) markers into one test.

Case Study

FoundationFOCUS™ CDx BRCA

|

Foundation Medicine partnered with Clovis Oncology to develop FoundationFocus CDx BRCA, the FDA-approved companion diagnostic test for Rubraca® (rucaparib), a PARP inhibitor therapy for BRCA-mutated ovarian cancer. The collaboration with Clovis is an example of Foundation Medicine’s unique value as a CDx partner.

Learn more about FoundationFOCUS CDx BRCA

Doctor and patient discussing testing options

Ready to discuss how a partnership can advance your drug development program?

Contact Us